Million A Tegenge (M A Tegenge, Million Tegenge)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Topics

Ejection Fraction

End Stage Renal Disease

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Haemophilia : the official journal of the World Federation of Hemophilia

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Tingting Zhou, Million A Tegenge, Basil Golding, John Scott
Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta-Analysis of Clinical Trials. Journal of clinical pharmacology (2023)
Iftekhar Mahmood, Million A Tegenge
Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. Journal of clinical pharmacology (2022)
Million A Tegenge, Artur A Belov, Megan Moncur, Richard Forshee, Telba Irony
Comparing clotting factors attributes across different methods of preference elicitation in haemophilia patients. Haemophilia : the official journal of the World Federation of Hemophilia 26 (5) (2020)
Million A Tegenge, Iftekhar Mahmood, Richard Forshee
Clinical Pharmacology Review of Plasma-derived and Recombinant Protein Products: CBER Experience and Perspectives on Model-Informed Drug Development. Haemophilia : the official journal of the World Federation of Hemophilia 25 (4) (2019)
Million A Tegenge, H Yang, R A Forshee
Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products. Haemophilia : the official journal of the World Federation of Hemophilia 23 (5) (2017)